Beijing Tongrentang (600085.SS)

Overall impact
B (68)

Commentary

Beijing Tongrentang is a strong overall performer. With a 'B' rating of 67.6 for overall impact (78th percentile compared to all companies), Beijing Tongrentang ranks 78th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 74 others, and ahead of Evolus, GenSight Biologics, Oyster Point Pharma and 73 others. On top material causes for Beijing Tongrentang's industry (Pharmaceuticals & Biotech), Beijing Tongrentang performs well in Disease Eradication (96.4 score), Improved Mental Health (84.7), Access to Affordable Healthcare (86.6) and 1 other cause where it received an 'A' score and performs poorly in Reduced Waste (34.9 score).
Impact
Cause 600085.SS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Beijing Tongrentang

Employees
17,284
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
600085.SS
Description
Beijing Tongrentang Co., Ltd engages in the scientific research, production, distribution, and sale of Chinese medicines in China. The company provides product dosage forms, such as pills, powders, wine preparations, capsules, and oral liquids in the areas of cardiovascular, gynecology, heat clearing class, respiratory system, nourishing and calming, digestive system, pediatrics, wind-dispelling and dampness-removing, orthopedics, five senses, dermatology, psychological, and food and wine. The company was founded in 1997 and is headquartered in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
Material causes
Ethos considers the following causes material for Beijing Tongrentang, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.